FDA 21 CFR 56: Institutional Review Boards
$0.00
21 CFR 56 applies to the Investigational Review Boards (IRBs) that monitor clinical investigations regulated by the FDA, including drugs, medical devices,ﾠbiological products, dietary supplements, infant formulas, and food & color additives.ﾠ
Requirements regarding record content, management, and retention can be found throughout this document.
| Issuing Body | FDA Regulations |
|---|
You may also like…
-
FDA Guidance: Computerized Systems Used in Clinical Investigations, 5/07
This May, 2007 FDA guidance incorporates a risk-based approach to Part 11 and recommendations on system SOPs, security, audit trails, and developer training.
$0.00 Add to cart -
FDA Draft Guidance: Use of Electronic Records and Electronic Signatures in Clinical Investigations under Part 11 – Q&A, 6/17
June 2017 Draft FDA Guidance intended to assist study sponsors, investigators, IRBs, and CROs in complying with 21 CFR Part 11, Electronic Records; Electronic Signatures.
$0.00 Add to cart -
FDA Guidance: Use of Electronic Informed Consent Questions and Answers, 12/16
This December 2016 guidance provides information regarding implementation of FDA-compliant electronic Informed Consent technologies and processes.
$0.00 Add to cart
